Cargando…
2298. Infections in Patients Receiving TVEC Therapy
BACKGROUND: Oncolytic viral immunotherapy is an emerging cancer treatment, but the infectious complications are not well described outside of clinical trials. Genetically engineered replication competent herpes simplex virus (HSV-1), commercially known as IMLGYIC® (AmGen) or talimogene laherparepvec...
Autores principales: | Robilotti, Elizabeth, Kamboj, Mini |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6809872/ http://dx.doi.org/10.1093/ofid/ofz360.1976 |
Ejemplares similares
-
2150. Discontinuation of Vancomycin-Resistant Enterococci (VRE) Surveillance and Contact Isolation in ICU and Transplant Units
por: Carlino, Sandra, et al.
Publicado: (2018) -
2298. Clinical and Demographic Characteristics of COVID-19 in Pediatric Patients in the United States
por: Ho, Milan, et al.
Publicado: (2022) -
2298. Penetration of SARS-CoV-2 Alpha, Delta, and Omicron Variants in the USA
por: Choi, Hosoon, et al.
Publicado: (2023) -
535. Transmission of Clostridium difficile (CD) From Patients ≤2 Years of Age in a Pediatric Oncology Setting
por: Robilotti, Elizabeth, et al.
Publicado: (2018) -
2298. Identifying and Addressing Implementation Barriers to Whole-Genome Sequencing (WGS) in State Public Health Laboratories
por: Oliver, Angela, et al.
Publicado: (2018)